CANCER / BIOMARKERI / PROTEOMICA

• Cancer proteomic studies might identify disease-related biomarkers for early cancer diagnosis and new surrogate biomarkers for therapy efficacy, but also for guidance of optimal anticancer drug combinations, enabling tailor-made therapy.
• Multiple technologies that measure expression levels of proteins in human samples offer a potential strategy for the detection and understanding of tumor formation.
• A major goal of the cancer biomarker field is to develop non-invasive tests that allow the detection of cancer at its earliest stages.
• Tumors are a heterogeneous group of neoplasms that appear to underlie individual patterns of growth, invasion, response to therapy and prognosis.
• Cancer is the most commune diseases, with poor prognosis and low survival rate
• Serum proteomic pattern diagnostics can offer specific signatures that can be used as a diagnostic classifier.
• The interest for proteomics increased lately because this approach has recently shown great promise in the detection of early-stage cancers.
• The array of serum markers comprises angiogenesis-related proteins, growth factors, cytokines, and enzymes and so on.
• Although challenging, proteomic profiling has recently become one of the most important areas in cancer research, and the majority of the currently available methodologies, such as xMAP technology and SELDI-TOF-MS, was used in human tumor research. This technology may provide a panel of serum markers for early identification and monitoring disease progression.
• Biomarker discovery for tumors is still continuing and the search for the best molecule or combination of serum compounds is even more up-to-date